^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

STEAP1-targeted antibody-drug conjugate

Related drugs:
7ms
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape. (PubMed, Curr Oncol Rep)
ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape. ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.
Review • Journal
|
STEAP1 (STEAP Family Member 1)
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)
1year
Targeting STEAP1 as an anticancer strategy. (PubMed, Front Oncol)
In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1.
Review • Journal • IO biomarker
|
STEAP1 (STEAP Family Member 1)
over1year
Quantitative proteomics of antibody-drug conjugates and chemotherapy targets in prostate cancer (AACR 2023)
Chemotherapy involves the use of anti-tubulins (docetaxel, cabazitaxel), platinum salts, and topoisomerase inhibitors (TOPO1, TOPO2A)...Biomarkers of resistance include ERCC1 (Platinum), TUBB3 (taxanes), ALDH1A1 (cyclophosphamide), while response biomarkers include TOPO1 (irinotecan, topotecan), TOPO2A (doxorubicin, epirubicin), and hENT1 (Gemcitabine)...ERCC1, a marker for resistance to platinum-based agents, was not detected in 26% of cases, potentially enabling a cisplatin/carboplatin-based regimen in 1/4th of prostate cancer patients...These include doxorubicin biomarker TOPO2A in 34% of cases with 10x range, gemcitabine biomarker hENT1 in 36% of cases (4x range), temozolomide biomarker MGMT (ND in 12% of cases)...Trop2 was quantitated in 93% of the cases and had wide range of 37x (437 -16267 amol/ µg). The capacity to multiplex 72 protein biomarkers from 2-3 FFPE sections yields a wealth of actionable information for clinical treatment or patient stratification in clinical trials.
IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CLDN18 (Claudin 18) • TOP2A (DNA topoisomerase 2-alpha) • ERCC1 (Excision repair cross-complementation group 1) • TUBB3 (Tubulin beta 3 class III) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • STEAP1 (STEAP Family Member 1) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)
|
cisplatin • carboplatin • gemcitabine • docetaxel • temozolomide • doxorubicin hydrochloride • cyclophosphamide • irinotecan • epirubicin • topotecan • cabazitaxel
over1year
Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review. (PubMed, Cureus)
ADCs seem to provide efficacy benefits, even with potential toxicity. The results of most prospective ongoing studies are still awaited, and a longer follow-up time is warranted to evaluate the real impact of ADCs in PCa.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD276 (CD276 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • STEAP1 (STEAP Family Member 1)
2years
Antibody-Drug Conjugates in Prostate Cancer: Where Are we? (PubMed, Clin Genitourin Cancer)
In prostate cancer, PSMA, STEAP1, TROP2, CD46 and B7-H3 are antigens currently being studied as targets for ADCs. In this paper, we discuss the composition of ADCs and focus on their application and challenges as treatment options in prostate cancer.
Review • Journal
|
CD276 (CD276 Molecule) • STEAP1 (STEAP Family Member 1)
over3years
Prostate Cancer Immunotherapy-Finally in From the Cold? (PubMed, Curr Oncol Rep)
Novel treatment strategies using new antigen-directed therapies, drugs targeting the immunosuppressive tumor microenvironment, and combination immunotherapy therapies show great potential and are currently in clinical development. In addition, a deeper understanding of predictors of response and resistance to immunotherapy in prostate cancer is allowing for a more personalized approach to therapy.
Journal • Review • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
TMB-L
|
Decipher Prostate Cancer Test
almost4years
Treating Prostate Cancer by Antibody-Drug Conjugates. (PubMed, Int J Mol Sci)
Therefore, we focus on recently published and ongoing trials designed to investigate the clinical activity of ADCs against prostate malignancy, characterizing these agents. Lastly, we briefly discuss some ADCs-related issues with corresponding strategies to overwhelm them, along with future perspectives for these promising novel compounds.
Review • Journal
|
CD276 (CD276 Molecule) • STEAP1 (STEAP Family Member 1)
almost4years
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer (clinicaltrials.gov)
P1/2, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
Clinical • Trial completion date • Trial primary completion date
|
STEAP1 (STEAP Family Member 1)
|
vandortuzumab vedotin (RG7450)
almost5years
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer (clinicaltrials.gov)
P1/2, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
Clinical • Trial completion date • Trial primary completion date
|
STEAP1 (STEAP Family Member 1)
|
vandortuzumab vedotin (RG7450)
almost6years
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer (clinicaltrials.gov)
P1/2, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
Clinical • Trial completion date • Trial primary completion date
|
STEAP1 (STEAP Family Member 1)
|
vandortuzumab vedotin (RG7450)